Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Kuei-Meng Wu"'
Autor:
Kuei-Meng Wu
Publikováno v:
Pharmaceuticals, Vol 2, Iss 3, Pp 77-81 (2009)
Many therapeutic agents are manufactured and administered in prodrug forms. In this paper, a new classification system for prodrugs is proposed to provide useful information about where in the body a prodrug is converted to the active drug. In this s
Externí odkaz:
https://doaj.org/article/f3253bc1329d4dda8e8461b5db874247
Publikováno v:
International Journal of Toxicology. 31:211-221
The timing of carcinogenicity studies in parallel with the clinical development of anti–human immunodeficiency virus (HIV) drugs has been flexible for most cases in the past. This includes postponement of the initiation of the studies and submissio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0672bff88f31e98c05ee667feb015bb3
https://doi.org/10.1177/1091581812439585
https://doi.org/10.1177/1091581812439585
Publikováno v:
Nature Biotechnology. 26:1077-1083
Although new botanical drugs pose many challenges for both industry and the FDA, approval of the first botanical prescription drug shows they can be successfully met.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a15c4a28e802b2f17e1ac29fb742d4
https://doi.org/10.1038/nbt1008-1077
https://doi.org/10.1038/nbt1008-1077
Autor:
James G. Farrelly, Kuei-Meng Wu
Publikováno v:
Toxicology. 236:1-6
Many therapeutic agents are prepared in prodrug forms, which are classified into Type I, II and subtypes A, B based on their sites of conversion. Recently, an increasing number of INDs have appeared as Type II prodrugs that often contain dual tracks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4e50a26230bc59534ae16fb066780dd
https://doi.org/10.1016/j.tox.2007.04.005
https://doi.org/10.1016/j.tox.2007.04.005
Autor:
Wendy Schmidt, Robert E. Osterberg, Estella Barry, Anita Bigger, Kuei-Meng Wu, Dou Jean, Herman Rhee, Tao Du, Harry Geyer, Conrad Chen, Abby Jacobs, Aisar Atrakchi, Joseph G. DeGeorge, Anwar Goheer, James G. Farrelly, Lois Freed
Publikováno v:
Toxicology Letters. 111:199-202
A recent survey was conducted across the therapeutic divisions within the CDER, U.S. FDA regarding the number of submissions related to botanical drug products over the past ten years. The overall number of botanical submissions as expressed in the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::899d70584d21990677afb0f53b147f49
https://doi.org/10.1016/s0378-4274(99)00152-6
https://doi.org/10.1016/s0378-4274(99)00152-6
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 56(1)
Genotoxicity testing is an important part of preclinical safety assessment of new drugs and is required prior to Phase I/II clinical trials. It is designed to detect genetic damage such as gene mutations and chromosomal aberration, which may be refle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7898feda14c52b8393593c7be4a65876
https://pubmed.ncbi.nlm.nih.gov/19782117
https://pubmed.ncbi.nlm.nih.gov/19782117
Publikováno v:
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 46(8)
Toxicological studies constitute an essential part of the effort in developing an herbal medicine into a drug product. The US food and drug administration (FDA) published a guidance to assist academic and industry sponsors in the development of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ece656cdc1b7685a5f2613254adb9570
https://pubmed.ncbi.nlm.nih.gov/18614266
https://pubmed.ncbi.nlm.nih.gov/18614266
Publikováno v:
The FASEB Journal. 22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::469648f6ab68fa200fc48e0d47529bed
https://doi.org/10.1096/fasebj.22.1_supplement.720.2
https://doi.org/10.1096/fasebj.22.1_supplement.720.2
Publikováno v:
The FASEB Journal. 22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d890162c57ed7b8131b711379cd115c
https://doi.org/10.1096/fasebj.22.1_supplement.720.3
https://doi.org/10.1096/fasebj.22.1_supplement.720.3
Autor:
Kuei-Meng Wu, James G. Farrelly
Publikováno v:
American journal of therapeutics. 13(2)
New drugs that enhance metabolism or clearance of thyroid hormones in rats often trigger a sequence of toxicity events during chronic administration: reduction of thyroxine, elevation of thyroid-stimulating hormone (TSH) levels, and thyroid gland hyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1840b1ee8f627cf92bf8431129f2c07d
https://pubmed.ncbi.nlm.nih.gov/16645431
https://pubmed.ncbi.nlm.nih.gov/16645431